JP2019502696A5 - - Google Patents

Download PDF

Info

Publication number
JP2019502696A5
JP2019502696A5 JP2018531529A JP2018531529A JP2019502696A5 JP 2019502696 A5 JP2019502696 A5 JP 2019502696A5 JP 2018531529 A JP2018531529 A JP 2018531529A JP 2018531529 A JP2018531529 A JP 2018531529A JP 2019502696 A5 JP2019502696 A5 JP 2019502696A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
compound according
disorder
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018531529A
Other languages
English (en)
Japanese (ja)
Other versions
JP7036725B2 (ja
JP2019502696A (ja
Filing date
Publication date
Priority claimed from GBGB1522179.9A external-priority patent/GB201522179D0/en
Application filed filed Critical
Publication of JP2019502696A publication Critical patent/JP2019502696A/ja
Publication of JP2019502696A5 publication Critical patent/JP2019502696A5/ja
Application granted granted Critical
Publication of JP7036725B2 publication Critical patent/JP7036725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018531529A 2015-12-16 2016-12-16 Kv3チャネルのヒダントインモジュレーター Expired - Fee Related JP7036725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522179.9 2015-12-16
GBGB1522179.9A GB201522179D0 (en) 2015-12-16 2015-12-16 Novel compounds
PCT/GB2016/053958 WO2017103604A1 (en) 2015-12-16 2016-12-16 Hydantoin modulators of kv3 channels

Publications (3)

Publication Number Publication Date
JP2019502696A JP2019502696A (ja) 2019-01-31
JP2019502696A5 true JP2019502696A5 (cg-RX-API-DMAC7.html) 2020-02-06
JP7036725B2 JP7036725B2 (ja) 2022-03-15

Family

ID=55274838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531529A Expired - Fee Related JP7036725B2 (ja) 2015-12-16 2016-12-16 Kv3チャネルのヒダントインモジュレーター

Country Status (7)

Country Link
US (1) US20200377485A1 (cg-RX-API-DMAC7.html)
EP (1) EP3390394B1 (cg-RX-API-DMAC7.html)
JP (1) JP7036725B2 (cg-RX-API-DMAC7.html)
CN (1) CN108430995A (cg-RX-API-DMAC7.html)
BR (1) BR112018012177A2 (cg-RX-API-DMAC7.html)
GB (1) GB201522179D0 (cg-RX-API-DMAC7.html)
WO (1) WO2017103604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
PL3867247T3 (pl) 2018-10-16 2024-12-09 Autifony Therapeutics Limited Nowe związki
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
US20220220095A1 (en) 2019-04-26 2022-07-14 H. Lundbeck A/S N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
CN113710318A (zh) 2019-04-26 2021-11-26 H.隆德贝克有限公司 作为Kv3钾通道激活剂的芳基磺酰基噻吩甲酰胺和芳基磺酰基呋喃甲酰胺
BR112022013339A2 (pt) 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
CA3226856A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
WO2026093398A1 (en) 2024-10-29 2026-05-07 Autifony Therapeutics Limited Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299383A (ja) * 1985-10-28 1987-05-08 Tokuyama Soda Co Ltd エ−テル化合物の製造方法
KR20050033663A (ko) * 2002-09-05 2005-04-12 메디비르 아베 비-뉴클레오시드 역전사효소 억제제
US20050080100A1 (en) * 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
EP1845087A1 (en) * 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
JP6112486B2 (ja) * 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
KR101862375B1 (ko) * 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
WO2012170931A2 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9273054B2 (en) * 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
JP2015517563A (ja) * 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Kv3阻害剤としてのヒダントイン誘導体
JP6226967B2 (ja) * 2012-06-06 2017-11-08 ヴァンダービルト ケミカルズ、エルエルシー 燃費効率がよい潤滑油
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
WO2015031036A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof

Similar Documents

Publication Publication Date Title
JP2015517563A5 (cg-RX-API-DMAC7.html)
JP2022505143A5 (cg-RX-API-DMAC7.html)
ES2660831T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
RU2409576C2 (ru) Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
JP2016511258A5 (cg-RX-API-DMAC7.html)
JP2018517746A5 (cg-RX-API-DMAC7.html)
WO2017040993A4 (en) Small molecule inhibitors of dyrk1a and uses thereof
TN2016000227A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides.
JP2019509291A5 (cg-RX-API-DMAC7.html)
JP2016538313A5 (cg-RX-API-DMAC7.html)
JP2017513894A5 (cg-RX-API-DMAC7.html)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2016525102A5 (cg-RX-API-DMAC7.html)
JP2010523522A5 (cg-RX-API-DMAC7.html)
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
JP2014514290A5 (cg-RX-API-DMAC7.html)
RU2015112914A (ru) Бензимидазолы в качестве активных агентов для центральной нервной системы
JP2020500866A5 (cg-RX-API-DMAC7.html)
JP2020520925A5 (cg-RX-API-DMAC7.html)
JP2019506367A5 (cg-RX-API-DMAC7.html)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2013507371A5 (cg-RX-API-DMAC7.html)
JP2020502230A5 (cg-RX-API-DMAC7.html)
JP2019520344A5 (cg-RX-API-DMAC7.html)
HK1255438A1 (zh) 用於治疗癌症的(s,e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺